Excellent. Now That is how our press release should have been written it's essentially a re-write that can be understood and appreciated by anyone interested.
She very nicely cleaned up Marwan's marred sentences for him as well:
"“There is hope that new therapies for Alzheimer’s that target the disease beyond amyloid … may slow progression … for many people with the earliest forms of the disease,” said Marwan Noel Sabbagh, MD, professor of neurology at the Barrow Neurological Institute in Arizona and chairman of the scientific advisory board at Anavex. “The advantage of … Anavex 2-73 … is that it is a small oral molecule that exerts clinical benefits on cognition and neurodegeneration and could be appealing because of its route of administration and excellent safety profile.”
Neurodegeneration and cognitive decline slow with Anavex 2-73 Benefits include slower rate of brain shrinkage, amyloid-beta protein reductions
Lindsey Shapiro, PhD avatar by Lindsey Shapiro, PhD | September 15, 2023
Definitely a keeper. Hire this gal to write all our press releases. She also adds here good info concerning the ATTENTION - AD extension trial, noting it's a 2 year trial ending next year (Aug-Sept?)... I would add (again) that according to my view of the timing of our filings for AD accelerated approval, we should have that trial completed a month or so after we get FDA's approval (or disapproval) decision. Which will be nice timing for their purposes. Similarly, I think we'll have a peer reviewed article on this trial out around May of next year. Also nicely timed if we really do file for AA by the end of 2023.
News 
Market Data 
Discover 
